Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab

Coronary Artery Disease

Volumn 12, Issue 3, 2001, Pages 245-253

  Holmes, Michael B ^a,b   Kabbani, Samer S ^a   Terrien, Christopher M ^a   Watkins, Matthew W ^a   Sobel, Burton E ^a   Schneider, David J ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Abciximab; Flow cytometry; Glycoprotein IIb IIIa inhibitors; P selectin; Tirofiban

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; ORBOFIBAN; TIROFIBAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DEGRANULATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; FLOW CYTOMETRY; HEART INFARCTION; HUMAN; INDIVIDUALIZATION; MALE; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; TYROSINE;

EID: 0035040324     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200105000-00011     Document Type: Article

References (21)

1. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
2. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
3. Inhibition of the platelet glycoprotein IIb-IIIa receptor with tirofiban in unstable angina and non-q wave myocardial infarction
4. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb-IIIa receptor in high-risk coronary angioplasty
6. Platelet glycoprotein IIb-IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization
7. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb-IIIa receptors
8. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects
9. Paradoxical inhibition of fibrinogen binding and potentiation of alpha granule release by specific types of inhibitors of glycoprotein IIb-IIIa
10. Differences between activation thresholds for platelet P-selectin and glycoprotein IIb-IIIa expression and their clinical implications
11. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy
12. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin
13. Differential effects of anticoagulants on the activation of platelets ex vivo
14. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: A potential contributor to cardiovascular risk
15. Optimizing antiplatelet therapy in patients with acute coronary syndromes: A role for monitoring platelet reactivity
16. Blood clotting in minimally altered whole blood
17. Optimally functional fiuorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation
18. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation
19. Platelet procoagulant complex assembly in a tissue factor-initiated system
20. Collagen-platelet interactions evidence for a direct interaction of collagen with platelet GP Ia/IIa and an indirect interaction with platelet GP IIb/IIIa mediated by adhesive proteins
21. Von willebrand factor binding to platelet GP Ib initiates signals for platelet activation